Eli Lilly Enforces 340B Data Submission Deadline as HRSA Declines to Intervene
Eli Lilly's deadline for hospitals to submit claims data to maintain 340B drug discounts has passed, with noncompliant hospitals now at risk of losing discounted pricing. The manufacturer issued a June 1 letter giving hospitals five days to comply with data submission requirements. The Health Resources and Services Administration (HRSA) did not respond to requests from hospital and pharmacy groups to intervene in the dispute. Hospitals that failed to meet the deadline may face immediate loss of 340B discounts on Lilly products, affecting their ability to purchase drugs at reduced rates under the federal program.
Medicaid managed care organizations that contract with safety-net hospitals relying on 340B discounts may face higher pharmacy costs if hospitals lose access to discounted drugs and pass those costs through to payers.
Pharmacy · Managed Care
You might also like